Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Mendelian Disorders Testing Market Trends

ID: MRFR/LS/4053-HCR
90 Pages
Rahul Gotadki
March 2026

Mendelian disorders testing market research report: by test type (carrier testing, diagnostic testing, new-born screening), by disorder (cystic fibrosis, sickle cell anemia), by end-user (hospitals, ascs, specialized clinics) – Global forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Mendelian Disorders Testing Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Mendelian Disorders Testing Market

The demand for Mendelian Disorders testing in the United States has been steadily increasing, reflecting a growing recognition of the significance of genetic testing in healthcare. Mendelian Disorders, also known as monogenic disorders, are caused by mutations in a single gene and often have a clear inheritance pattern. This market demand surge can be attributed to various factors, including advancements in genetic testing technologies, heightened awareness of the role of genetics in health, and an increasing prevalence of Mendelian Disorders within the population.

Advancements in genetic testing technologies have played a pivotal role in driving the demand for Mendelian Disorders testing in the US. The field of genomics has witnessed remarkable progress, with the development of high-throughput sequencing technologies, such as next-generation sequencing (NGS). These technologies enable comprehensive analysis of an individual's genetic makeup, allowing healthcare professionals to identify specific gene mutations associated with Mendelian Disorders more efficiently and accurately. As the cost of genetic testing continues to decrease, it has become more accessible to a broader range of individuals, contributing to the growing demand for Mendelian Disorders testing.

There has been a notable increase in public awareness regarding the role of genetics in determining health outcomes. This heightened awareness is driven by factors such as increased media coverage of genetic discoveries, educational initiatives, and the growing popularity of direct-to-consumer genetic testing services. As individuals become more informed about the potential genetic underpinnings of certain health conditions, there is a corresponding increase in demand for Mendelian Disorders testing to assess and understand their own genetic risk factors.

The prevalence of Mendelian Disorders within the population has also contributed significantly to the rising demand for testing services. With an increasing understanding of the genetic basis of various diseases, healthcare professionals are better equipped to identify individuals at risk of Mendelian Disorders and provide targeted genetic testing. This proactive approach to healthcare, focusing on early identification and intervention, has driven the demand for testing services to prevent or manage these disorders effectively.

The US Mendelian Disorders testing market is witnessing a surge in the development and availability of genetic testing panels tailored to specific disorders. These panels allow for the simultaneous analysis of multiple genes associated with a particular Mendelian Disorder, streamlining the testing process and providing comprehensive insights. This trend is especially crucial for conditions with overlapping symptoms, enabling more accurate and timely diagnoses.

In addition to traditional healthcare settings, the demand for Mendelian Disorders testing has extended to research and pharmaceutical sectors. Genetic testing plays a vital role in the identification of potential therapeutic targets and the development of personalized medicine. The collaboration between research institutions, pharmaceutical companies, and genetic testing laboratories has fueled innovation and expanded the scope of Mendelian Disorders testing applications.

As the demand for Mendelian Disorders testing continues to rise, there is a growing emphasis on genetic counseling services to support individuals and families in understanding and interpreting their test results. Genetic counselors play a crucial role in helping individuals make informed decisions about their healthcare based on their genetic information, contributing to a more comprehensive and patient-centered approach to genetic testing.

Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Mendelian Disorders Testing Market?

<p>The Mendelian Disorders Testing Market was valued at 0.43 USD Billion in 2024.</p>

What is the projected market size for the Mendelian Disorders Testing Market by 2035?

<p>The market is projected to reach 1.228 USD Billion by 2035.</p>

What is the expected CAGR for the Mendelian Disorders Testing Market during the forecast period?

<p>The expected CAGR for the market from 2025 to 2035 is 10.01%.</p>

Which companies are considered key players in the Mendelian Disorders Testing Market?

<p>Key players include Illumina, Thermo Fisher Scientific, Agilent Technologies, and F. Hoffmann-La Roche.</p>

What are the main segments of the Mendelian Disorders Testing Market?

<p>The main segments include carrier testing, diagnostic testing, newborn screening, and prenatal testing.</p>

How did the carrier testing segment perform in 2024?

In 2024, the carrier testing segment was valued at approximately 0.086 USD Billion.

What is the projected value of the diagnostic testing segment by 2035?

The diagnostic testing segment is expected to reach around 0.372 USD Billion by 2035.

Which disorder types are most prevalent in the Mendelian Disorders Testing Market?

Cystic fibrosis and sickle cell anemia are among the most prevalent disorder types, with values of 0.05 and 0.07 USD Billion in 2024, respectively.

What is the expected growth for specialized clinics in the Mendelian Disorders Testing Market?

The specialized clinics segment is projected to grow to approximately 0.368 USD Billion by 2035.

How does the market's growth potential compare across different end users?

Hospitals are expected to dominate the market, with a valuation of 0.615 USD Billion projected for 2035.

Market Summary

As per Market Research Future analysis, the Mendelian Disorders Testing Market was estimated at 0.43 USD Billion in 2024. The Mendelian Disorders Testing industry is projected to grow from USD 0.473 Billion in 2025 to USD 1.228 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.01% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Mendelian Disorders Testing Market is poised for substantial growth driven by technological advancements and increasing awareness.

  • North America remains the largest market for Mendelian disorders testing, driven by robust healthcare infrastructure and high demand for genetic testing.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and increasing awareness of genetic disorders.
  • Carrier testing continues to dominate the market, while diagnostic testing is experiencing rapid growth due to advancements in technology.
  • Key market drivers include technological advancements in genetic testing and the rising prevalence of Mendelian disorders, which are propelling demand across various segments.

Market Size & Forecast

2024 Market Size 0.43 (USD Billion)
2035 Market Size 1.228 (USD Billion)
CAGR (2025 - 2035) 10.01%
Largest Regional Market Share in 2024 Americas

Major Players

Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), F. Hoffmann-La Roche (CH), PerkinElmer (US), Myriad Genetics (US), Invitae (US), GeneDx (US), Sema4 (US)

Market Trends

The Mendelian Disorders Testing Market is currently experiencing a notable evolution, driven by advancements in genetic research and technology. As understanding of genetic conditions deepens, the demand for accurate and efficient testing methods is increasing. This market encompasses a range of services, including carrier screening, prenatal testing, and diagnostic testing for various Mendelian disorders. The integration of next-generation sequencing technologies is particularly influential, as it enhances the ability to identify genetic mutations with greater precision. Furthermore, the growing awareness of genetic disorders among healthcare providers and patients is likely to propel market growth, as individuals seek proactive measures for health management. In addition, the regulatory landscape surrounding genetic testing is evolving, which may impact the Mendelian Disorders Testing Market. Regulatory bodies are increasingly focusing on ensuring the accuracy and reliability of genetic tests, which could lead to improved standards and practices within the industry. Moreover, collaborations between academic institutions and biotechnology companies are fostering innovation, potentially leading to the development of novel testing methodologies. As the market continues to mature, it appears poised for further expansion, driven by technological advancements and a heightened focus on personalized medicine.

Technological Advancements in Genetic Testing

The Mendelian Disorders Testing Market is witnessing rapid technological progress, particularly with the advent of next-generation sequencing. This innovation allows for comprehensive analysis of genetic material, enabling the identification of mutations associated with various disorders. As these technologies become more accessible, they are likely to enhance the accuracy and efficiency of testing, thereby attracting more patients and healthcare providers.

Increased Awareness and Demand for Genetic Testing

There is a growing recognition of the importance of genetic testing among both healthcare professionals and the general public. This heightened awareness is driving demand for testing services, as individuals seek to understand their genetic predispositions. Consequently, the Mendelian Disorders Testing Market is expected to expand as more people opt for carrier screening and diagnostic testing.

Regulatory Developments and Standardization

The regulatory environment surrounding genetic testing is evolving, with an emphasis on ensuring the reliability and accuracy of tests. Regulatory bodies are likely to implement stricter guidelines, which may lead to improved quality standards in the Mendelian Disorders Testing Market. This focus on standardization could enhance consumer confidence and promote wider adoption of testing services.

Mendelian Disorders Testing Market Market Drivers

Rising Prevalence of Mendelian Disorders

The increasing prevalence of Mendelian disorders is a critical factor driving the Mendelian Disorders Testing Market. Conditions such as cystic fibrosis, sickle cell disease, and Huntington's disease are becoming more recognized, leading to a greater need for effective diagnostic solutions. Epidemiological studies indicate that approximately 1 in 200 individuals are affected by a Mendelian disorder, underscoring the urgency for comprehensive testing options. As awareness of these conditions grows, so does the demand for genetic testing services that can provide accurate diagnoses and inform treatment decisions. This rising prevalence is likely to stimulate market growth, as healthcare systems strive to address the needs of affected populations.

Regulatory Developments and Standardization

The Mendelian Disorders Testing Market is influenced by evolving regulatory frameworks aimed at ensuring the safety and efficacy of genetic testing. Regulatory bodies are increasingly focusing on standardizing testing procedures and validating the accuracy of results. This is particularly crucial as the market expands, with numerous new testing services entering the landscape. Enhanced regulations not only foster consumer trust but also encourage innovation among testing providers. As a result, companies are investing in compliance and quality assurance measures, which may lead to improved testing outcomes. The establishment of clear guidelines is anticipated to facilitate market growth, as stakeholders navigate the complexities of genetic testing.

Technological Advancements in Genetic Testing

The Mendelian Disorders Testing Market is experiencing a transformative phase due to rapid technological advancements. Innovations such as next-generation sequencing (NGS) and CRISPR gene editing are revolutionizing the landscape of genetic testing. These technologies enable more accurate and efficient identification of genetic mutations associated with Mendelian disorders. For instance, NGS allows for the simultaneous analysis of multiple genes, significantly reducing the time and cost associated with traditional testing methods. As a result, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over the next five years. This growth is driven by the increasing adoption of these advanced technologies in clinical settings, enhancing diagnostic capabilities and patient outcomes.

Increased Awareness and Demand for Genetic Testing

The rising awareness regarding genetic disorders and the benefits of early diagnosis is propelling the Mendelian Disorders Testing Market forward. Educational initiatives and advocacy from healthcare professionals have led to a heightened understanding of genetic testing among the public. This awareness is reflected in the increasing demand for testing services, as individuals seek proactive measures for health management. According to recent surveys, nearly 60% of individuals express interest in genetic testing for hereditary conditions. This trend is likely to continue, as more people recognize the importance of genetic information in making informed healthcare decisions. Consequently, the market is expected to expand, driven by this growing consumer demand.

Integration of Genetic Testing in Clinical Practice

The integration of Mendelian disorders testing into routine clinical practice is a significant driver for the Mendelian Disorders Testing Market. Healthcare providers are increasingly recognizing the value of genetic testing in diagnosing and managing hereditary conditions. This integration is supported by clinical guidelines recommending genetic testing for specific patient populations, thereby enhancing the overall quality of care. As healthcare systems adopt personalized medicine approaches, the demand for genetic testing is expected to rise. Furthermore, the collaboration between genetic testing laboratories and healthcare providers is likely to streamline the testing process, making it more accessible to patients. This trend is indicative of a broader shift towards precision medicine, which is anticipated to bolster market growth.

Market Segment Insights

By Type: Carrier Testing (Largest) vs. Diagnostic Testing (Fastest-Growing)

<p>In the Mendelian Disorders Testing Market, the carrier testing segment holds the largest share, primarily driven by increasing awareness and demand for genetic insights among prospective parents. This testing type is pivotal in identifying carriers of genetic mutations, which helps in making informed reproductive choices. On the other hand, the diagnostic testing segment is observing the fastest growth due to advancements in technology and a rise in genetic disorder diagnoses. With a growing emphasis on early detection, this segment is gaining significant traction.</p>

<p>Carrier Testing (Dominant) vs. Diagnostic Testing (Emerging)</p>

<p>Carrier testing is currently the dominant force in the Mendelian Disorders Testing Market, characterized by its pivotal role in reproductive decision-making. It provides comprehensive insights into genetic carrier status, ensuring that individuals and families can make informed choices regarding family planning. This segment benefits from increased public awareness and evolving societal norms surrounding genetic information. Conversely, the diagnostic testing segment is emerging rapidly, fueled by advancements in sequencing technologies and a heightened focus on early detection of genetic disorders. This segment appeals to healthcare providers and patients alike, driven by a need for accurate diagnosis and management of genetic conditions.</p>

By Disorder Type: Cystic Fibrosis (Largest) vs. Sickle Cell Anemia (Fastest-Growing)

<p>In the Mendelian Disorders Testing Market, the distribution of market share among different disorder types illustrates a clear hierarchy, with Cystic Fibrosis emerging as the dominant disorder type. This is followed closely by Sickle Cell Anemia, which is gaining traction, especially in regions with high prevalence. Other notable disorder types such as Tay-Sachs, Gaucher's Disease, and Huntington's Disease contribute to the market, but their shares remain comparatively smaller. Overall, the diversity of disorders reflects varying healthcare needs and genetic testing demands across regions. Growth trends in the Mendelian Disorders Testing Market indicate a surge in demand for Sickle Cell Anemia testing, primarily driven by increased awareness and screening programs. Advances in genetic testing technologies and growing understanding of these disorders also play a critical role. Health initiatives promoting early diagnosis significantly enhance the accessibility and acceptance of testing, thereby propelling the market forward. Cystic Fibrosis remains a steadfast segment due to its established testing protocols and patient care frameworks, continuing to attract investments and research.</p>

<p>Cystic Fibrosis (Dominant) vs. Sickle Cell Anemia (Emerging)</p>

<p>Cystic Fibrosis is recognized as a dominant segment in the Mendelian Disorders Testing Market, primarily due to well-established screening and diagnostic guidelines that facilitate early identification and intervention. This disorder has fostered significant advancements in treatment protocols, thus reinforcing the need for regular testing. In contrast, Sickle Cell Anemia is emerging rapidly, driven by an increase in genetic awareness and state-sponsored screening initiatives, particularly in high-prevalence regions. As healthcare systems become increasingly focused on personalized medicine, both disorders illustrate the dynamic landscape of genetic testing, with Cystic Fibrosis solidifying its foothold and Sickle Cell Anemia positioned for accelerated growth.</p>

By End User: Hospitals (Largest) vs. Specialized Clinics (Fastest-Growing)

<p>The Mendelian Disorders Testing Market showcases a diverse landscape of end users, predominantly led by hospitals, which account for a significant share of the market. Ambulatory surgical centers (ASCs) also contribute meaningfully, though they hold a smaller fraction compared to hospitals. Specialized clinics have emerged as vital players, rapidly capturing attention due to their focused offerings and specialized care. In recent years, the growth trend within this segment has been propelled by several factors. Hospitals continue to prioritize comprehensive screening and diagnostic capabilities, while increasing patient awareness drives demand at specialized clinics. Furthermore, technological advancements in genetic testing and a push for personalized medicine are encouraging ASCs to adopt these testing methods, potentially altering the competitive dynamics of the market.</p>

<p>Hospitals (Dominant) vs. Specialized Clinics (Emerging)</p>

<p>Hospitals remain the dominant force in the Mendelian Disorders Testing Market due to their extensive resources, established patient infrastructure, and comprehensive care capabilities. They typically have access to advanced diagnostic tools and a multidisciplinary approach to genetic testing, which positions them as first-line facilities for testing and management of Mendelian disorders. In contrast, specialized clinics are emerging quickly, catering to patients who seek targeted <a href="https://www.marketresearchfuture.com/reports/genetic-counseling-market-19215" target="_blank" title="genetic counseling">genetic counseling</a> and testing services tailored to specific conditions. This shift towards specialization is driven by patient demand for customized care, leading specialists in genetic disorders to establish outpatient models that enhance accessibility and focus on individualized treatment plans.</p>

Get more detailed insights about Mendelian Disorders Testing Market Research Report- Global Forecast till 2035

Regional Insights

North America : Leading Innovation and Research

North America is the largest market for Mendelian disorders testing, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing awareness of genetic disorders, and supportive regulatory frameworks. The demand for personalized medicine and genetic testing is on the rise, further propelled by government initiatives promoting research and development in genomics. The United States is the leading country in this market, with significant contributions from key players such as Illumina, Thermo Fisher Scientific, and Myriad Genetics. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. Canada also plays a vital role, with increasing investments in genetic research and testing services, enhancing the overall market dynamics.

Europe : Regulatory Support and Growth

Europe is the second-largest market for Mendelian disorders testing, holding around 30% of the global market share. The region benefits from robust healthcare systems and increasing government support for genetic research. Regulatory bodies are actively promoting the integration of genetic testing into clinical practice, which is driving demand. The European Union's initiatives to standardize genetic testing protocols are also contributing to market growth. Leading countries in this region include Germany, France, and the United Kingdom, where significant investments in healthcare technology are being made. The competitive landscape features major players like F. Hoffmann-La Roche and Agilent Technologies, which are focusing on innovative solutions to enhance testing accuracy. The presence of numerous startups in the genetic testing space is also fostering a dynamic market environment.

Asia-Pacific : Emerging Market Potential

Asia-Pacific is witnessing rapid growth in the Mendelian disorders testing market, accounting for approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of genetic disorders, and advancements in technology. Countries like China and India are leading this growth, driven by government initiatives to enhance healthcare access and promote genetic research. China is the largest market in the region, with significant investments in biotechnology and genetic testing infrastructure. India is also emerging as a key player, with a growing number of diagnostic laboratories offering genetic testing services. The competitive landscape is evolving, with both established companies and new entrants focusing on innovative testing solutions to meet the rising demand.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the Mendelian disorders testing market, holding about 5% of the global share. The growth is driven by increasing awareness of genetic disorders and the need for advanced healthcare solutions. Governments are beginning to recognize the importance of genetic testing, leading to initiatives aimed at improving healthcare infrastructure and access to genetic services. Countries like South Africa and the UAE are at the forefront of this growth, with investments in healthcare technology and genetic research. The competitive landscape is still developing, with a mix of local and international players entering the market. The presence of key players is expected to increase as demand for genetic testing rises, creating new opportunities for growth in the region.

Key Players and Competitive Insights

The Mendelian Disorders Testing Market is characterized by a dynamic competitive landscape, driven by advancements in genetic testing technologies and an increasing prevalence of genetic disorders. Key players such as Illumina (US), Thermo Fisher Scientific (US), and F. Hoffmann-La Roche (CH) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on next-generation sequencing technologies, which are pivotal in providing comprehensive genetic insights, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of diagnostic solutions that cater to various genetic testing needs. F. Hoffmann-La Roche (CH) is strategically positioned through its robust research and development initiatives, aiming to integrate precision medicine into routine clinical practice. Collectively, these strategies foster a competitive environment that prioritizes technological advancement and collaborative efforts.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the Mendelian Disorders Testing Market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive innovation, thereby shaping the overall market dynamics.

In August 2025, Illumina (US) announced a strategic partnership with a leading healthcare provider to expand access to its genetic testing services. This collaboration is expected to enhance patient access to advanced genetic diagnostics, thereby potentially increasing the adoption of Mendelian disorder testing. The strategic importance of this partnership lies in its ability to bridge the gap between cutting-edge technology and clinical application, ultimately improving patient outcomes.

In September 2025, Thermo Fisher Scientific (US) launched a new suite of genetic testing solutions aimed at streamlining the diagnostic process for Mendelian disorders. This launch is significant as it reflects the company's commitment to innovation and its response to the growing demand for rapid and accurate genetic testing. By enhancing its product offerings, Thermo Fisher Scientific (US) positions itself as a leader in the market, catering to the evolving needs of healthcare providers and patients alike.

In July 2025, F. Hoffmann-La Roche (CH) expanded its portfolio by acquiring a biotechnology firm specializing in gene therapy. This acquisition is indicative of Roche's strategy to diversify its offerings and integrate advanced therapeutic solutions with diagnostic capabilities. The strategic importance of this move lies in its potential to create a comprehensive approach to managing Mendelian disorders, combining diagnostics with innovative treatment options.

As of October 2025, current competitive trends in the Mendelian Disorders Testing Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their technological capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift underscores the importance of not only meeting market demands but also anticipating future trends in genetic testing.

Key Companies in the Mendelian Disorders Testing Market include

Industry Developments

Future Outlook

Mendelian Disorders Testing Market Future Outlook

The Mendelian Disorders Testing Market is projected to grow at a 10.01% CAGR from 2025 to 2035, driven by advancements in genetic research, increasing awareness, and technological innovations.

New opportunities lie in:

  • Development of AI-driven genetic analysis platforms
  • Expansion of telehealth services for remote testing
  • Partnerships with healthcare providers for integrated testing solutions

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

Market Segmentation

Mendelian Disorders Testing Market Type Outlook

  • carrier testing
  • diagnostic testing
  • new-born screening
  • predictive & pre-symptomatic testing
  • prenatal testing
  • others

Mendelian Disorders Testing Market End User Outlook

  • hospitals
  • ambulatory surgical centers (ASCs)
  • specialized clinics

Mendelian Disorders Testing Market Disorder Type Outlook

  • cystic fibrosis
  • sickle cell anemia
  • severe combined immunodeficiency (SCID)
  • Tay-Sachs disorder
  • polycystic kidney disorder
  • Gaucher's disease
  • Huntington's disease
  • neurofibromatosis
  • thalassemia
  • familial hypercholesterolemia
  • others

Report Scope

MARKET SIZE 2024 0.43(USD Billion)
MARKET SIZE 2025 0.473(USD Billion)
MARKET SIZE 2035 1.228(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 10.01% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), F. Hoffmann-La Roche (CH), PerkinElmer (US), Myriad Genetics (US), Invitae (US), GeneDx (US), Sema4 (US)
Segments Covered test type, disorder, end-user
Key Market Opportunities Advancements in genomic technologies enhance accuracy and accessibility in the Mendelian Disorders Testing Market.
Key Market Dynamics Rising demand for personalized medicine drives innovation and competition in the Mendelian Disorders Testing market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Mendelian Disorders Testing Market?

<p>The Mendelian Disorders Testing Market was valued at 0.43 USD Billion in 2024.</p>

What is the projected market size for the Mendelian Disorders Testing Market by 2035?

<p>The market is projected to reach 1.228 USD Billion by 2035.</p>

What is the expected CAGR for the Mendelian Disorders Testing Market during the forecast period?

<p>The expected CAGR for the market from 2025 to 2035 is 10.01%.</p>

Which companies are considered key players in the Mendelian Disorders Testing Market?

<p>Key players include Illumina, Thermo Fisher Scientific, Agilent Technologies, and F. Hoffmann-La Roche.</p>

What are the main segments of the Mendelian Disorders Testing Market?

<p>The main segments include carrier testing, diagnostic testing, newborn screening, and prenatal testing.</p>

How did the carrier testing segment perform in 2024?

In 2024, the carrier testing segment was valued at approximately 0.086 USD Billion.

What is the projected value of the diagnostic testing segment by 2035?

The diagnostic testing segment is expected to reach around 0.372 USD Billion by 2035.

Which disorder types are most prevalent in the Mendelian Disorders Testing Market?

Cystic fibrosis and sickle cell anemia are among the most prevalent disorder types, with values of 0.05 and 0.07 USD Billion in 2024, respectively.

What is the expected growth for specialized clinics in the Mendelian Disorders Testing Market?

The specialized clinics segment is projected to grow to approximately 0.368 USD Billion by 2035.

How does the market's growth potential compare across different end users?

Hospitals are expected to dominate the market, with a valuation of 0.615 USD Billion projected for 2035.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type (USD Billion)
    2. | | 4.1.1 carrier testing
    3. | | 4.1.2 diagnostic testing
    4. | | 4.1.3 new-born screening
    5. | | 4.1.4 predictive & pre-symptomatic testing
    6. | | 4.1.5 prenatal testing
    7. | | 4.1.6 others
    8. | 4.2 Healthcare, BY Disorder Type (USD Billion)
    9. | | 4.2.1 cystic fibrosis
    10. | | 4.2.2 sickle cell anemia
    11. | | 4.2.3 severe combined immunodeficiency (SCID)
    12. | | 4.2.4 Tay-Sachs disorder
    13. | | 4.2.5 polycystic kidney disorder
    14. | | 4.2.6 Gaucher's disease
    15. | | 4.2.7 Huntington's disease
    16. | | 4.2.8 neurofibromatosis
    17. | | 4.2.9 thalassemia
    18. | | 4.2.10 familial hypercholesterolemia
    19. | | 4.2.11 others
    20. | 4.3 Healthcare, BY End User (USD Billion)
    21. | | 4.3.1 hospitals
    22. | | 4.3.2 ambulatory surgical centers (ASCs)
    23. | | 4.3.3 specialized clinics
    24. | 4.4 Healthcare, BY Region (USD Billion)
    25. | | 4.4.1 North America
    26. | | | 4.4.1.1 US
    27. | | | 4.4.1.2 Canada
    28. | | 4.4.2 Europe
    29. | | | 4.4.2.1 Germany
    30. | | | 4.4.2.2 UK
    31. | | | 4.4.2.3 France
    32. | | | 4.4.2.4 Russia
    33. | | | 4.4.2.5 Italy
    34. | | | 4.4.2.6 Spain
    35. | | | 4.4.2.7 Rest of Europe
    36. | | 4.4.3 APAC
    37. | | | 4.4.3.1 China
    38. | | | 4.4.3.2 India
    39. | | | 4.4.3.3 Japan
    40. | | | 4.4.3.4 South Korea
    41. | | | 4.4.3.5 Malaysia
    42. | | | 4.4.3.6 Thailand
    43. | | | 4.4.3.7 Indonesia
    44. | | | 4.4.3.8 Rest of APAC
    45. | | 4.4.4 South America
    46. | | | 4.4.4.1 Brazil
    47. | | | 4.4.4.2 Mexico
    48. | | | 4.4.4.3 Argentina
    49. | | | 4.4.4.4 Rest of South America
    50. | | 4.4.5 MEA
    51. | | | 4.4.5.1 GCC Countries
    52. | | | 4.4.5.2 South Africa
    53. | | | 4.4.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Illumina (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Thermo Fisher Scientific (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Agilent Technologies (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 F. Hoffmann-La Roche (CH)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 PerkinElmer (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Myriad Genetics (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Invitae (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 GeneDx (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Sema4 (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE
    4. | 6.4 US MARKET ANALYSIS BY DISORDER TYPE
    5. | 6.5 US MARKET ANALYSIS BY END USER
    6. | 6.6 CANADA MARKET ANALYSIS BY TYPE
    7. | 6.7 CANADA MARKET ANALYSIS BY DISORDER TYPE
    8. | 6.8 CANADA MARKET ANALYSIS BY END USER
    9. | 6.9 EUROPE MARKET ANALYSIS
    10. | 6.10 GERMANY MARKET ANALYSIS BY TYPE
    11. | 6.11 GERMANY MARKET ANALYSIS BY DISORDER TYPE
    12. | 6.12 GERMANY MARKET ANALYSIS BY END USER
    13. | 6.13 UK MARKET ANALYSIS BY TYPE
    14. | 6.14 UK MARKET ANALYSIS BY DISORDER TYPE
    15. | 6.15 UK MARKET ANALYSIS BY END USER
    16. | 6.16 FRANCE MARKET ANALYSIS BY TYPE
    17. | 6.17 FRANCE MARKET ANALYSIS BY DISORDER TYPE
    18. | 6.18 FRANCE MARKET ANALYSIS BY END USER
    19. | 6.19 RUSSIA MARKET ANALYSIS BY TYPE
    20. | 6.20 RUSSIA MARKET ANALYSIS BY DISORDER TYPE
    21. | 6.21 RUSSIA MARKET ANALYSIS BY END USER
    22. | 6.22 ITALY MARKET ANALYSIS BY TYPE
    23. | 6.23 ITALY MARKET ANALYSIS BY DISORDER TYPE
    24. | 6.24 ITALY MARKET ANALYSIS BY END USER
    25. | 6.25 SPAIN MARKET ANALYSIS BY TYPE
    26. | 6.26 SPAIN MARKET ANALYSIS BY DISORDER TYPE
    27. | 6.27 SPAIN MARKET ANALYSIS BY END USER
    28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
    29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY DISORDER TYPE
    30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER
    31. | 6.31 APAC MARKET ANALYSIS
    32. | 6.32 CHINA MARKET ANALYSIS BY TYPE
    33. | 6.33 CHINA MARKET ANALYSIS BY DISORDER TYPE
    34. | 6.34 CHINA MARKET ANALYSIS BY END USER
    35. | 6.35 INDIA MARKET ANALYSIS BY TYPE
    36. | 6.36 INDIA MARKET ANALYSIS BY DISORDER TYPE
    37. | 6.37 INDIA MARKET ANALYSIS BY END USER
    38. | 6.38 JAPAN MARKET ANALYSIS BY TYPE
    39. | 6.39 JAPAN MARKET ANALYSIS BY DISORDER TYPE
    40. | 6.40 JAPAN MARKET ANALYSIS BY END USER
    41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
    42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY DISORDER TYPE
    43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER
    44. | 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
    45. | 6.45 MALAYSIA MARKET ANALYSIS BY DISORDER TYPE
    46. | 6.46 MALAYSIA MARKET ANALYSIS BY END USER
    47. | 6.47 THAILAND MARKET ANALYSIS BY TYPE
    48. | 6.48 THAILAND MARKET ANALYSIS BY DISORDER TYPE
    49. | 6.49 THAILAND MARKET ANALYSIS BY END USER
    50. | 6.50 INDONESIA MARKET ANALYSIS BY TYPE
    51. | 6.51 INDONESIA MARKET ANALYSIS BY DISORDER TYPE
    52. | 6.52 INDONESIA MARKET ANALYSIS BY END USER
    53. | 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
    54. | 6.54 REST OF APAC MARKET ANALYSIS BY DISORDER TYPE
    55. | 6.55 REST OF APAC MARKET ANALYSIS BY END USER
    56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. | 6.57 BRAZIL MARKET ANALYSIS BY TYPE
    58. | 6.58 BRAZIL MARKET ANALYSIS BY DISORDER TYPE
    59. | 6.59 BRAZIL MARKET ANALYSIS BY END USER
    60. | 6.60 MEXICO MARKET ANALYSIS BY TYPE
    61. | 6.61 MEXICO MARKET ANALYSIS BY DISORDER TYPE
    62. | 6.62 MEXICO MARKET ANALYSIS BY END USER
    63. | 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
    64. | 6.64 ARGENTINA MARKET ANALYSIS BY DISORDER TYPE
    65. | 6.65 ARGENTINA MARKET ANALYSIS BY END USER
    66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISORDER TYPE
    68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    69. | 6.69 MEA MARKET ANALYSIS
    70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY DISORDER TYPE
    72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER
    73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY DISORDER TYPE
    75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER
    76. | 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
    77. | 6.77 REST OF MEA MARKET ANALYSIS BY DISORDER TYPE
    78. | 6.78 REST OF MEA MARKET ANALYSIS BY END USER
    79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. | 6.80 RESEARCH PROCESS OF MRFR
    81. | 6.81 DRO ANALYSIS OF HEALTHCARE
    82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. | 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    86. | 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    87. | 6.87 HEALTHCARE, BY DISORDER TYPE, 2024 (% SHARE)
    88. | 6.88 HEALTHCARE, BY DISORDER TYPE, 2024 TO 2035 (USD Billion)
    89. | 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE)
    90. | 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY END USER, 2025-2035 (USD Billion)
    7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    8. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
    9. | | 7.3.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    10. | | 7.3.3 BY END USER, 2025-2035 (USD Billion)
    11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    12. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
    13. | | 7.4.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    14. | | 7.4.3 BY END USER, 2025-2035 (USD Billion)
    15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
    17. | | 7.5.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    18. | | 7.5.3 BY END USER, 2025-2035 (USD Billion)
    19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    20. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
    21. | | 7.6.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    22. | | 7.6.3 BY END USER, 2025-2035 (USD Billion)
    23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
    25. | | 7.7.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    26. | | 7.7.3 BY END USER, 2025-2035 (USD Billion)
    27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
    29. | | 7.8.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    30. | | 7.8.3 BY END USER, 2025-2035 (USD Billion)
    31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    32. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
    33. | | 7.9.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    34. | | 7.9.3 BY END USER, 2025-2035 (USD Billion)
    35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    36. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
    37. | | 7.10.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    38. | | 7.10.3 BY END USER, 2025-2035 (USD Billion)
    39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
    41. | | 7.11.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    42. | | 7.11.3 BY END USER, 2025-2035 (USD Billion)
    43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
    45. | | 7.12.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    46. | | 7.12.3 BY END USER, 2025-2035 (USD Billion)
    47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    48. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
    49. | | 7.13.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    50. | | 7.13.3 BY END USER, 2025-2035 (USD Billion)
    51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
    53. | | 7.14.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    54. | | 7.14.3 BY END USER, 2025-2035 (USD Billion)
    55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    56. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
    57. | | 7.15.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    58. | | 7.15.3 BY END USER, 2025-2035 (USD Billion)
    59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    60. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
    61. | | 7.16.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    62. | | 7.16.3 BY END USER, 2025-2035 (USD Billion)
    63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
    65. | | 7.17.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    66. | | 7.17.3 BY END USER, 2025-2035 (USD Billion)
    67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    68. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
    69. | | 7.18.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    70. | | 7.18.3 BY END USER, 2025-2035 (USD Billion)
    71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    72. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
    73. | | 7.19.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    74. | | 7.19.3 BY END USER, 2025-2035 (USD Billion)
    75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
    77. | | 7.20.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    78. | | 7.20.3 BY END USER, 2025-2035 (USD Billion)
    79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    80. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
    81. | | 7.21.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    82. | | 7.21.3 BY END USER, 2025-2035 (USD Billion)
    83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
    85. | | 7.22.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    86. | | 7.22.3 BY END USER, 2025-2035 (USD Billion)
    87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
    89. | | 7.23.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    90. | | 7.23.3 BY END USER, 2025-2035 (USD Billion)
    91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    92. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
    93. | | 7.24.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    94. | | 7.24.3 BY END USER, 2025-2035 (USD Billion)
    95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    96. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
    97. | | 7.25.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    98. | | 7.25.3 BY END USER, 2025-2035 (USD Billion)
    99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
    101. | | 7.26.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    102. | | 7.26.3 BY END USER, 2025-2035 (USD Billion)
    103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
    105. | | 7.27.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    106. | | 7.27.3 BY END USER, 2025-2035 (USD Billion)
    107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    108. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
    109. | | 7.28.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    110. | | 7.28.3 BY END USER, 2025-2035 (USD Billion)
    111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
    113. | | 7.29.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    114. | | 7.29.3 BY END USER, 2025-2035 (USD Billion)
    115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    116. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
    117. | | 7.30.2 BY DISORDER TYPE, 2025-2035 (USD Billion)
    118. | | 7.30.3 BY END USER, 2025-2035 (USD Billion)
    119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    120. | | 7.31.1
    121. | 7.32 ACQUISITION/PARTNERSHIP
    122. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • carrier testing
  • diagnostic testing
  • new-born screening
  • predictive & pre-symptomatic testing
  • prenatal testing
  • others

Healthcare By Disorder Type (USD Billion, 2025-2035)

  • cystic fibrosis
  • sickle cell anemia
  • severe combined immunodeficiency (SCID)
  • Tay-Sachs disorder
  • polycystic kidney disorder
  • Gaucher's disease
  • Huntington's disease
  • neurofibromatosis
  • thalassemia
  • familial hypercholesterolemia
  • others

Healthcare By End User (USD Billion, 2025-2035)

  • hospitals
  • ambulatory surgical centers (ASCs)
  • specialized clinics
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓